Australia's Inoviq surges on agreement with Canadian biotech firm

Inoviq

13/10/2022 02:49

** Shares of Australia's Inoviq  IIQ.AX  rise as much as
7.7% to A$0.63, their highest since Sept. 23
    ** The medical diagnostics co announces that it has signed
contract research agreement with Canadian biotech firm Nicoya
Lifesciences Inc  urn:newsml:reuters.com:*:nASXc8jtq9
    ** Says agreement to transfer, develop and evaluate a
prototype SubB2M‐based test on the next generation Alto digital
SPR instrument
    ** Adds the SubB2M-based SPR test will initially be
developed for use as a cancer risk assessment test
    ** Stock has fallen 51.1% this year, as of last close
 (Reporting by Rishav Chatterjee in Bengaluru)
 ((Rishav.Chatterjee@thomsonreuters.com;))